Some non-overlapping mechanisms of resistance to trastuzumab and lapatinib likely exist in erbB2-positive breast cancers, as lapatinib has been approved by the FDA to treat erbB2-positive MBC that has progressed on trastuzumab-based therapy [19]. The gene discussed is ERBB2; the disease is breast carcinoma.